Nakajima Katsuyuki, Nakano Takamitsu, Tanaka Akira
Japan Immunoresearch Laboratories, Co. Ltd., Takasaki, Gunma, and Department of Health and Nutrition, College of Human and Environmental Studies, Kanto-Gakuin University, Yokohama, Japan.
Clin Chim Acta. 2006 May;367(1-2):36-47. doi: 10.1016/j.cca.2005.12.013. Epub 2006 Jan 30.
A tremendous number of articles on oxidized LDL (Ox-LDL) and scavenger receptor in macrophage have been published since Steinberg proposed Ox-LDL hypothesis as the major cause of atherosclerosis. This hypothesis has provided strong support for the efficacy of LDL lowering drugs, indicating that lowering LDL means lowering Ox-LDL in vivo. This manuscript proposed a new oxidative modification hypothesis that remnant lipoproteins determined as remnant-like lipoprotein particles (RLP), not LDL are the major oxidized lipoproteins in plasma, resulting from the plasma concentration of these oxidized lipoproteins. Remnant lipoproteins may play a pivotal role for the initiation of atherosclerosis via lectin-like oxidized LDL receptor-1 (LOX-1) in endothelial cells. Isolated remnant lipoproteins were found to be oxidized or susceptible to be oxidized in plasma, not necessary to be further oxidized in vitro as Ox-LDL. High similarity of proatherogenic and proinflammatory properties of isolated Ox-LDL and remnant lipoporteins have been reported and predicted the presence of similar oxidized phospholipids in both lipoproteins as bioactive components. These results suggest the possibility that reducing plasma remnant lipoproteins rather than LDL should be the target for hyperlipidemic therapy especially in patients with metabolic syndrome for the prevention of endothelial dysfunction in the initiation of atherosclerosis.
自从斯坦伯格提出氧化型低密度脂蛋白(Ox-LDL)假说作为动脉粥样硬化的主要病因以来,已经发表了大量关于巨噬细胞中氧化型低密度脂蛋白和清道夫受体的文章。该假说为降低低密度脂蛋白药物的疗效提供了有力支持,表明降低低密度脂蛋白意味着在体内降低氧化型低密度脂蛋白。本手稿提出了一种新的氧化修饰假说,即被确定为残粒样脂蛋白颗粒(RLP)而非低密度脂蛋白的残粒脂蛋白是血浆中的主要氧化脂蛋白,这是由这些氧化脂蛋白的血浆浓度决定的。残粒脂蛋白可能通过内皮细胞中的凝集素样氧化型低密度脂蛋白受体-1(LOX-1)在动脉粥样硬化的起始过程中起关键作用。已发现分离出的残粒脂蛋白在血浆中被氧化或易于被氧化,不像氧化型低密度脂蛋白那样需要在体外进一步氧化。已报道分离出的氧化型低密度脂蛋白和残粒脂蛋白在促动脉粥样硬化和促炎特性方面具有高度相似性,并预测这两种脂蛋白中存在相似的氧化磷脂作为生物活性成分。这些结果表明,降低血浆残粒脂蛋白而非低密度脂蛋白应成为高脂血症治疗的靶点,尤其是对于代谢综合征患者,以预防动脉粥样硬化起始阶段的内皮功能障碍。